Pterygium Excision with Conjunctival Limbal Allograft — Cost, Top Hospitals & Success Rates | MyMedicPlus

A pterygium (plural: pterygia) is a benign, wedge-shaped growth of abnormal fibrovascular conjunctival tissue that extends from the white of the eye (sclera) onto the transparent cornea. The name derives from the Greek word for wing, reflecting its characteristic triangular shape. Although non-cancerous, pterygium can cause chronic irritation, redness, blurred vision, and significant astigmatism — and in advanced cases can obscure the visual axis entirely.

Pterygium excision with conjunctival limbal allograft (CLAU) is the gold-standard surgical approach for removing moderate-to-advanced pterygium and transplanting healthy donor conjunctival tissue carrying limbal stem cells to resurface the defect. These stem cells are critical — they repopulate the ocular surface and act as a biological barrier against pterygium regrowth.

Unlike the older bare sclera technique, which simply cuts out the growth and leaves the underlying sclera exposed, CLAU covers the excision site with tissue transplanted from a cadaveric or living donor eye. This dramatically reduces the 50–80% recurrence rate seen with bare sclera excision down to approximately 5–15%. CLAU is particularly indicated when the patient's own conjunctiva cannot be harvested (e.g., both eyes are affected, or previous surgery has compromised the fellow eye's tissue).

The procedure is performed under local or topical anaesthesia as a day-case (outpatient) surgery and typically takes 30–60 minutes per eye. Recovery involves lubricating drops, topical anti-inflammatory medications, and UV protection for several weeks.

Pterygium excision with CLAU is primarily performed for:

• Primary pterygium: First-occurrence pterygium encroaching on the cornea causing irritation, visual disturbance, or astigmatism (corneal warping).
• Recurrent pterygium: Regrowth following previous excision, particularly when prior conjunctival tissue was used or when bare sclera technique was employed.
• Bilateral pterygium: When both eyes are affected and autograft harvest from the fellow eye would compromise its ocular surface.
• Advanced or aggressive pterygium: Rapidly progressing lesions or those reaching or crossing the visual axis (pupillary zone), significantly impairing vision.
• Pterygium with significant astigmatism: Growths inducing more than 1.5 dioptres of irregular astigmatism that cannot be adequately corrected with spectacles or contact lenses.
• Cosmetically unacceptable pterygium: Patients with significant redness or visible tissue growth causing psychological or social distress, particularly when conservative management has failed.

Surgery is generally deferred in small, stable pterygia that cause minimal symptoms. Conservative management with lubricating drops, UV-protective sunglasses, and avoiding dusty environments is recommended for non-progressive lesions.

Ideal candidates for pterygium excision with CLAU are evaluated by an ophthalmologist based on several criteria:

• Pterygium extent: Lesions extending more than 2 mm onto the cornea, or those approaching the visual axis, are typically considered for surgical removal.
• Symptom burden: Persistent redness, irritation, foreign body sensation, tearing, or vision blur despite adequate topical lubrication for 3–6 months.
• Progressive growth: Documented increase in pterygium size over 6–12 months of observation.
• Donor tissue availability: Availability of appropriately screened cadaveric conjunctival tissue from an accredited eye bank, or willingness to use living related donor tissue in some settings.
• General ocular health: Adequate intraocular pressure, no active ocular infection, and no contraindications to topical anaesthesia or steroid use post-operatively.

Relative contraindications include active ocular surface infection, severely compromised immune status (which may affect graft integration), and patients who are unable to comply with post-operative medication regimens. Patients with a history of prior glaucoma filtering surgery near the planned excision site require careful planning to protect filtering blebs.

Preoperative assessment typically includes slit-lamp biomicroscopy, corneal topography to quantify astigmatism, and baseline visual acuity measurement.

Several surgical strategies exist for pterygium removal; the optimal choice depends on pterygium characteristics, availability of donor tissue, and surgeon expertise:

Conjunctival Limbal Allograft (CLAU)

The procedure described on this page. A cadaveric (or living donor) conjunctival graft carrying limbal stem cells is sutured or glued into the excision site. Advantages include no risk to the patient's fellow eye and an adequate tissue supply regardless of pterygium bilaterality. Immunological rejection is rare given the immune-privileged status of the ocular surface, though topical steroids are used post-operatively as precaution.

Conjunctival Autograft (CAG)

Tissue is harvested from the patient's own superior bulbar conjunctiva (same or fellow eye). Success rates and recurrence rates are comparable to CLAU. Preferred when only one eye is affected and the fellow eye has sufficient healthy conjunctiva. Avoids any theoretical risk of allograft rejection.

Amniotic Membrane Transplantation (AMT)

A sheet of preserved human amniotic membrane is used to cover the excision site. AMT has anti-inflammatory and anti-fibrotic properties and is useful in cases with significant inflammation or where conjunctival tissue is scarce. Recurrence rates are slightly higher than with conjunctival grafts (approximately 10–30%).

Adjunctive Mitomycin C (MMC)

An anti-proliferative chemotherapy agent applied intraoperatively to the bare sclera for 2–5 minutes. MMC reduces fibroblast activity and lowers recurrence risk but carries risks of scleral melting, corneal toxicity, and secondary glaucoma — hence it is reserved for high-risk or recurrent cases and is not standard in primary pterygium excision with graft.

Tissue Adhesive (Fibrin Glue) vs. Sutures

Grafts may be secured with absorbable sutures or fibrin tissue glue (e.g., Tisseel). Fibrin glue significantly reduces operating time and post-operative discomfort, and studies show equivalent or superior graft stability to sutures. It is widely preferred where available.

• Definitive removal: Complete excision of the pterygium tissue, eliminating chronic redness, irritation, and foreign body sensation.
• Vision restoration: Removal of corneal invasion restores optical clarity, reduces irregular astigmatism, and can improve uncorrected and corrected visual acuity.
• Low recurrence rate: CLAU achieves recurrence rates of 5–15%, far superior to the 50–80% rate with bare sclera excision.
• No risk to the fellow eye: Unlike autograft, CLAU does not require harvesting tissue from the patient's second eye, which is particularly important in bilateral pterygium.
• Cosmetic improvement: Eliminates the visible red-pink fibrovascular growth, restoring a white, clear ocular surface and improving appearance.
• Outpatient procedure: Surgery is completed in 30–60 minutes under local anaesthesia; patients return home the same day.
• Durable results: When recurrence does not occur within the first 12 months, long-term stability is generally excellent.
• Improved contact lens tolerance: Removing the elevated pterygium tissue may restore the ability to wear contact lenses comfortably.

Pterygium excision with CLAU is generally safe, but as with any surgery, risks exist:

• Recurrence (5–15%): The most common long-term complication. Risk is higher in younger patients, those with aggressive pterygia, UV-exposed individuals, and those in tropical climates.
• Graft-related complications: Graft displacement, retraction, or partial dehiscence, particularly in the first week before tissue integration. Fibrin glue or suture loosening can contribute.
• Allograft rejection: Rare given the immune-privileged ocular surface, but low-grade inflammation mimicking rejection may occur. Managed with intensified topical steroid therapy.
• Infection: Post-operative conjunctivitis or, rarely, endophthalmitis. Risk is minimised with prophylactic topical antibiotics.
• Corneal scarring: Residual stromal haze in the cornea from the pterygium head may persist and cause lasting irregular astigmatism.
• Diplopia (double vision): If the medial or inferior rectus muscle is inadvertently damaged during excision, temporary or permanent diplopia may result.
• Scleral thinning: Rare; more common when mitomycin C is used as adjunctive therapy.
• Dry eye exacerbation: Disruption of goblet cells in the conjunctiva can worsen pre-existing dry eye symptoms post-operatively.
• Subconjunctival haemorrhage: Common, typically resolves within 2–3 weeks without intervention.

Patients should report any sudden worsening of pain, vision loss, or severe discharge to their surgeon promptly, as these may indicate infection or graft failure requiring urgent intervention.

Post-operative care is essential for optimal healing and minimising recurrence:

Immediate Post-Operative Period (Days 1–7)

The eye is patched for 24 hours after surgery. Patients are prescribed topical antibiotic drops (e.g., moxifloxacin) 4 times daily, topical corticosteroid drops (e.g., prednisolone acetate 1%) 4–6 times daily, and preservative-free lubricating drops frequently throughout the day. Pain is typically mild and managed with oral paracetamol. The eye should not be rubbed.

Early Recovery (Weeks 2–4)

Redness, mild swelling, and a foreign body sensation are expected as the graft integrates. Follow-up visits at day 7 and week 3–4 allow the surgeon to check graft adherence, monitor for early recurrence signs, and taper steroid drops according to the inflammatory response.

Late Recovery (Months 1–3)

Steroid drops are gradually tapered over 6–12 weeks to prevent rebound inflammation while avoiding steroid-induced intraocular pressure elevation. Lubricating drops are continued for comfort. UV-protective wraparound sunglasses with polarised lenses are strongly recommended outdoors — long-term protection from UV radiation is the single most important preventive measure against recurrence.

Restrictions

• No swimming for 4 weeks
• No contact lens wear for 6–8 weeks
• Avoid dusty, smoky environments for 4 weeks
• Avoid eye rubbing for 6 weeks
• Drive only when vision is comfortable and not blurred by medications

The total cost of pterygium excision with CLAU varies significantly depending on:

• Geography: Costs in the US typically range from USD 2,000–4,500 per eye. In the UK (private), GBP 1,500–3,000. In medical tourism destinations such as India, Thailand, or Turkey, all-inclusive costs range from USD 300–900 per eye with equivalent-quality outcomes at JCI-accredited centres.
• Graft technique: CLAU (allograft) may carry slightly higher tissue procurement costs than autograft, particularly if certified eye bank tissue is required. Fibrin glue adds modest cost over sutures but reduces operating time.
• Anaesthesia type: Local anaesthesia (most common) is less expensive than general anaesthesia, which is occasionally used in anxious patients or children.
• Adjunctive treatments: Use of mitomycin C or amniotic membrane adds to procedural cost.
• Surgeon experience: High-volume pterygium surgeons with fellowship training in cornea/external disease may charge premium fees but typically deliver lower recurrence rates.
• Facility fees: Outpatient surgical centre fees vary widely; teaching hospitals may offer subsidised rates.
• Post-operative medications: Topical steroid and antibiotic drops for 4–12 weeks add USD 50–200 depending on brand and country.

Patients are encouraged to request itemised quotes covering surgeon, facility, anaesthesia, tissue procurement, post-operative visits, and medications when comparing providers internationally.

Not all pterygia require surgery. The following non-surgical and minimally invasive alternatives are appropriate for milder cases:

• Observation: Small, non-progressive pterygium causing minimal symptoms may simply be monitored every 6–12 months without intervention.
• Topical lubricants: Preservative-free artificial tears (e.g., carboxymethylcellulose, sodium hyaluronate) reduce friction and irritation, improving comfort without altering the pterygium itself.
• Topical vasoconstrictors: Drops containing oxymetazoline or naphazoline reduce redness temporarily but do not treat the underlying growth and should not be used long-term.
• Topical anti-inflammatory drops: Short courses of low-potency topical steroids or non-steroidal anti-inflammatory drugs (NSAIDs) can reduce acute inflammation and irritation during flare-ups.
• UV protection: Wraparound sunglasses with UV400 protection, wide-brimmed hats, and avoidance of prolonged outdoor UV exposure can slow pterygium progression significantly and are first-line preventive advice.
• Anti-VEGF injections (investigational): Subconjunctival bevacizumab (Avastin) injections have been studied as a method to reduce pterygium vascularity and size, but evidence for sustained benefit remains limited, and this approach is not standard of care.

Surgery remains the only definitive treatment for pterygium removal. Non-surgical options are palliative and do not prevent continued pterygium growth.